Safety, tolerability, and pharmacokinetics/pharmacodynamics of JMT103 in patients with bone metastases from solid tumors

Safety, tolerability, and pharmacokinetics/pharmacodynamics of JMT103 in patients with bone metastases from solid tumors

Bone metastases are common complications of solid tumors. The outcome is poor despite major progress in cancer therapies. We describe a multicenter, open-label, phase 1, dose escalation and expansion trial of JMT103, a novel fully humanized receptor activator of nuclear factor kappa-B ligand (RANKL)...

Full description

Bibliographic Details
Main Authors: Xu Liang, Junli Xue, Xiaoxiao Ge, Jin Li, Huiping Li, Liqiong Xue, Lijun Di, Wenbo Tang, Guohong Song, Qun Li, Hanfang Jiang, Wei Zhao, Fengjuan Lin, Bin Shao, Xiugao Yang, Zhufeng Wu, Tianyi Zhang, Chenchen Wang, Ye Guo
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Oncology
Subjects:
bone metastasis
JMT103
RANKL
phase 1 study
pharmacokinetics
N-telopeptide
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.971594/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.971594/full

Similar Items